表紙:米国の過活動膀胱治療薬の市場 (抗コリン作用薬、β-3アドレナリン受容体作動薬):産業分析と将来展望
市場調査レポート
商品コード
757839

米国の過活動膀胱治療薬の市場 (抗コリン作用薬、β-3アドレナリン受容体作動薬):産業分析と将来展望

United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)

出版日: | 発行: Koncept Analytics | ページ情報: 英文 69 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.28円
米国の過活動膀胱治療薬の市場 (抗コリン作用薬、β-3アドレナリン受容体作動薬):産業分析と将来展望
出版日: 2018年12月17日
発行: Koncept Analytics
ページ情報: 英文 69 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、米国国内の過活動膀胱 (OAB) 治療薬の市場について分析し、疾患の概要や疫学的状態、患者数の動向予測、OAB治療薬の市場規模の動向見通し、製品別の詳細動向、OABと前立腺肥大症 (BPH) の合併症の市場動向 (患者数、治療薬の市場規模)、主な市場促進・抑制要因、企業間市場競争の状態、主要企業のプロファイルなどについて調査しております。

第1章 市場概要

  • 過活動膀胱 (OAB) について
  • 症状と診断
  • 治療
  • 過活動膀胱と前立腺肥大症 (BPH) の合併症

第2章 米国市場の分析

  • 過活動膀胱 (OAB) 治療薬の市場
    • 過活動膀胱治療薬:市場規模の予測値 (金額ベース)
    • 過活動膀胱治療薬:市場規模、薬剤クラス別
    • 抗コリン作用薬:市場規模の予測値 (金額ベース)
    • β-3アドレナリン受容体作動薬:市場規模の予測値 (金額ベース)
    • β-3アドレナリン受容体作動薬:薬剤別の市場普及率
    • ビベグロン:市場収益額の予測
    • ビベグロン:処方量の予測
    • ミラベグロン:処方量の予測
    • 過活動膀胱の患者数の予測
    • 過活動膀胱の治療済み患者数の予測
    • 過活動膀胱治療薬の処方量の予測
  • OAB・BPH合併症の治療薬の市場
    • OAB・BPH合併症の患者数の予測
    • β-3アドレナリン受容体作動薬:市場規模の予測値 (金額ベース)
    • β-3アドレナリン受容体作動薬:薬剤別の市場普及率
    • ビベグロン:市場収益額の予測
    • ビベグロン:処方量の予測
    • ミラベグロン:処方量の予測

第3章 市場のダイナミクス

  • 成長促進要因
  • 主な傾向と動静
  • 課題

第4章 競争環境

  • 世界市場
    • 市場収益額の比較:企業別
    • 市場収益額と株式時価総額の比較:企業別

第5章 企業プロファイル

  • アステラス製薬
    • 事業概要
    • 主な財務指標
    • 事業戦略
  • 久光製薬
  • Pfizer Inc.
  • Allergan Plc.
目次

Overactive bladder (OAB) syndrome is a chronic medical condition which has a significant impact on the quality of life in a major amount of the population. Overactive bladder is the name given to a group of urinary symptoms that include a strong, uncontrollable urge to urinate at unexpected times, which may result in urine leakage (incontinence), and frequent urination during the day and night. OAB affects performance of daily activities and social functions such as work, traveling, physical exercise, sleep, and sexual function. OAB is a prevalent condition that affects the lives of millions of adults in the US and around the world. An estimated 30 million Americans suffer from overactive bladder, which is uncomfortable, disturbing, and potentially severe.

The treatment approaches for OAB includes behavioral therapy, such as bladder training and pelvic floor exercises. Second line treatment includes pharmacological intervention, historically with anticholinergic medications and more recently with the novel Beta 3 agonist mirabegron. For patients with persistent OAB symptoms, third-line treatment includes procedural therapy using BOTOX injected directly into the bladder to induce temporary muscle paralysis or neuromodulation to enhance neural signals and inhibit reflex detrusor contraction.

The US Overactive Bladder market is set to experience favorable growth driven by factors such rising ageing population, increasing health care expenditure, growing obese population, surging diabetic prevalence and increasing coffee intake. The major trends observed in this market include advancing innovative therapies, increasing awareness for OAB and development of gene therapy. However, the growth of the market is constrained by challenges such as entry of generic drugs in the market, stringent regulations and side effects of oral therapies of OAB.

The report "United States Overactive Bladder Market (Anticholinergics & Beta 3 Adrenoreceptor Agonists): Industry Analysis & Outlook (2020-2030)" analyses the development of the respective market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Astellas Pharma Inc., Hisamitsu Pharmaceutical Co., Inc., Pfizer Inc. and Allergan Plc. are being profiled along with their key financials and strategies for growth.

Table of Contents

1. Market Overview

  • 1.1 Overactive Bladder
  • 1.2 Symptoms & Diagnosis
  • 1.3 Treatment
  • 1.4 Overactive Bladder with BPH

2. US Market Analysis

  • 2.1 Overactive Bladder Market
    • 2.1.1 US Overactive Bladder Market Forecast by Value
    • 2.1.2 US Overactive Bladder Market by Drug Class
    • 2.1.3 US Anticholinergics Market Forecast by Value
    • 2.1.4 US Beta 3 Adrenoreceptor Agonists Market Forecast by Value
    • 2.1.5 US Beta 3 Adrenoreceptor Agonists Market Penetration by Drug
    • 2.1.6 US Vibegron Drug Revenue Forecast
    • 2.1.7 US Vibegron Prescriptions Volume Forecast
    • 2.1.8 US Mirabegron Prescriptions Volume Forecast
    • 2.1.9 US Overactive Bladder Patient Population Forecast
    • 2.1.10 US Overactive Bladder Treated Patient Population Forecast
    • 2.1.11 US Overactive Bladder Prescriptions Volume Forecast
  • 2.2 Overactive Bladder Market with BPH
    • 2.2.1 US Overactive Bladder with BPH Patient Population Forecast
    • 2.2.2 US Beta 3 Adrenoreceptor Agoinst Market by Penetration Rate
    • 2.2.3 US Beta 3 Adrenoreceptor Agoinst Market Penetration by Drug
    • 2.2.4 US Vibegron Drug Revenue Forecast
    • 2.2.5 US Vibegron Prescriptions Volume Forecast
    • 2.2.6 US Mirabegron Prescriptions Volume Forecast

3. Market Dynamics

  • 3.1 Growth Drivers
    • 3.1.1 Rising Ageing Population
    • 3.1.2 Increasing Health Care Expenditure
    • 3.1.3 Growing Obese Population
    • 3.1.4 Surging Diabetic Prevalence
    • 3.1.5 Increasing Coffee Intake
  • 3.2 Key Trends & Development
    • 3.2.1 Advancing Innovative Therapies
    • 3.2.2 Rising Awareness for OAB
    • 3.2.3 Development of Gene Therapy
  • 3.3 Challenges
    • 3.3.1 Entry of Generic Drugs
    • 3.3.2 Stringent Regulations
    • 3.3.3 Side Effects of Oral Therapies

4. Competition

  • 4.1 Global Market
    • 4.1.1 Revenue Comparison by Company
    • 4.1.2 Market Cap Comparison by Company

5. Company Profiles

  • 5.1 Astellas Pharma Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Financial Overview
    • 5.1.3 Business Strategies
  • 5.2 Hisamitsu Pharmaceutical Co., Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Financial Overview
    • 5.2.3 Business Strategies
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Financial Overview
    • 5.3.3 Business Strategies
  • 5.4 Allergan Plc.
    • 5.4.1 Business Overview
    • 5.4.2 Financial Overview
    • 5.4.3 Business Strategies

List of Charts

  • Normal Bladder versus Overactive Bladder
  • OAB Treatment Approaches
  • US Overactive Bladder Market Forecast by Value (2020-2030)
  • US Overactive Bladder Market by Drug Class (2020/2030)
  • US Anticholinergics Market Forecast by Value (2020-2030)
  • US Beta 3 Adrenoreceptor Agonists Market Forecast by Value (2020-2030)
  • US Beta 3 Adrenoreceptor Agonists Market Penetration by Drug (2020/2024/2030)
  • US Vibegron Drug Revenue Forecast (2020-2030)
  • US Vibegron Prescriptions Volume Forecast (2020-2030)
  • US Mirabegron Prescriptions Volume Forecast (2020-2030)
  • US Overactive Bladder Patient Population Forecast (2020-2030)
  • US Overactive Bladder Treated Patient Population Forecast (2020-2030)
  • US Overactive Bladder Prescriptions Volume Forecast (2020-2030)
  • US Overactive Bladder with BPH Patient Population Forecast (2020-2030)
  • US Beta 3 Adrenoreceptor Agoinst Market by Penetration Rate (2020-2030)
  • US Beta 3 Adrenoreceptor Agoinst Market Penetration by Drug (2021/2024/2030)
  • US Vibegron Drug Revenue Forecast (2021-2030)
  • US Vibegron Prescriptions Volume Forecast (2021-2030)
  • US Mirabegron Prescriptions Volume Forecast (2021-2030)
  • US Ageing Population (65 years & Above) (2013-2017)
  • US Healthcare Expenditure; 1990-2020 (%)
  • US Obese Population (20 years & Above) (2008-2017)
  • US Diagnosed Diabetic Population (2010-2017)
  • Domestic Consumption of Coffee in the US (2014-2018)
  • Revenue Comparison by Company (2017)
  • Market Cap Comparison by Company (2017)
  • Astellas Pharma Sales by Business Segments (2018)
  • Astellas Pharma Sales and Net Income (2014-2018)
  • Hisamitsu Pharmaceutical Sales by Business Segments (2018)
  • Hisamitsu Pharma Net Sales and Net Income (2014-2018)
  • Hisamitsu Pharmaceutical Research & Development Expenditure (2014-2018)
  • Pfizer Inc.'s Revenue Share by Major Business Segment (2017)
  • Pfizer Inc.'s Revenue and Net Income (2013-2017)
  • Pfizer Inc. R&D Expenses (2015-2017)
  • Allergan Plc Net Revenues by Business Segments (2017)
  • Allergan Plc Net Revenues and Net Income (Loss) (2013-2017)
  • Allergan Plc Research and Development Expenditures (2015-2017)

List of Tables

  • Astellas Pharma Major Product Approvals & Launches (2018)
  • Hisamitsu Pharmaceutical Product Approvals (2018)
  • Major Business Segments of the Pfizer Inc. (2017)
  • Pfizer Major Agreements (2018)